Frontline-matched sibling donor transplant of aplastic anemia patients using primed versus steady-state bone marrow grafts
Abstract Priming donors with G-CSF before BM harvest is reported to improve engraftment and GvHD in recipients. These effects are highly desirable when transplanting patients with non-neoplastic hematologic diseases, particularly AA patients. Here we retrospectively report the outcomes of 39 AA patients receiving a primed BM graft from MSD to 43 patients receiving a steady-state BM graft from MSD, otherwise transplanted using a uniform transplant platform. The graft had higher TNC and CD34 cell concentrations in the primed group (p < 0.001), and that was reflected in higher TNC and CD34 doses per kilogram of recipient in the primed group (p = 0.004 and 0.03, respectively). The OS for primed BM graft recipients was 97.4% and 78.9% for the steady-state BM graft recipients, p-value = 0.01. The cumulative incidence of death without GF was 2.6% in the primed group and 16.3% in the steady-state group, p-value = 0.03. There was no difference in GvHD incidence between the two groups. We confirm that priming improved the TNC and CD34 graft concentration and cell dose; this evidence along with other reported studies constitute reasonable evidence to prove that BM priming improve engraftment. We observed no increase in GvHD using primed BM graft..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:101 |
|---|---|
| Enthalten in: |
Annals of hematology - 101(2021), 2 vom: 31. Okt., Seite 421-428 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
El Fakih, Riad [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 |
|---|
| doi: |
10.1007/s00277-021-04708-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2077763086 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2077763086 | ||
| 003 | DE-627 | ||
| 005 | 20230518165025.0 | ||
| 007 | tu | ||
| 008 | 221220s2021 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00277-021-04708-4 |2 doi | |
| 035 | |a (DE-627)OLC2077763086 | ||
| 035 | |a (DE-He213)s00277-021-04708-4-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a El Fakih, Riad |e verfasserin |0 (orcid)0000-0003-4498-3865 |4 aut | |
| 245 | 1 | 0 | |a Frontline-matched sibling donor transplant of aplastic anemia patients using primed versus steady-state bone marrow grafts |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 | ||
| 520 | |a Abstract Priming donors with G-CSF before BM harvest is reported to improve engraftment and GvHD in recipients. These effects are highly desirable when transplanting patients with non-neoplastic hematologic diseases, particularly AA patients. Here we retrospectively report the outcomes of 39 AA patients receiving a primed BM graft from MSD to 43 patients receiving a steady-state BM graft from MSD, otherwise transplanted using a uniform transplant platform. The graft had higher TNC and CD34 cell concentrations in the primed group (p < 0.001), and that was reflected in higher TNC and CD34 doses per kilogram of recipient in the primed group (p = 0.004 and 0.03, respectively). The OS for primed BM graft recipients was 97.4% and 78.9% for the steady-state BM graft recipients, p-value = 0.01. The cumulative incidence of death without GF was 2.6% in the primed group and 16.3% in the steady-state group, p-value = 0.03. There was no difference in GvHD incidence between the two groups. We confirm that priming improved the TNC and CD34 graft concentration and cell dose; this evidence along with other reported studies constitute reasonable evidence to prove that BM priming improve engraftment. We observed no increase in GvHD using primed BM graft. | ||
| 650 | 4 | |a SAA | |
| 650 | 4 | |a Primed BM | |
| 650 | 4 | |a Steady-state BM | |
| 650 | 4 | |a Mobilized donors | |
| 650 | 4 | |a MSD | |
| 650 | 4 | |a Graft | |
| 700 | 1 | |a Alfraih, Feras |4 aut | |
| 700 | 1 | |a Alhayli, Saud |4 aut | |
| 700 | 1 | |a Ahmed, Syed Osman |4 aut | |
| 700 | 1 | |a Shaheen, Marwan |4 aut | |
| 700 | 1 | |a Chaudhri, Naeem |4 aut | |
| 700 | 1 | |a Alsharif, Fahad |4 aut | |
| 700 | 1 | |a Hanbali, Amr |4 aut | |
| 700 | 1 | |a Alshaibani, Alfadel |4 aut | |
| 700 | 1 | |a Alotaibi, Ahmad S. |4 aut | |
| 700 | 1 | |a Alharbi, Bander |4 aut | |
| 700 | 1 | |a AlYahya, Faisal Mohammed |4 aut | |
| 700 | 1 | |a Rawas, Wedian M. |4 aut | |
| 700 | 1 | |a Ghabashi, Emad |4 aut | |
| 700 | 1 | |a Kotb, Ahmed |4 aut | |
| 700 | 1 | |a Elhassan, Tusneem |4 aut | |
| 700 | 1 | |a Rasheed, Walid |4 aut | |
| 700 | 1 | |a Alzahrani, Hazzaa |4 aut | |
| 700 | 1 | |a Almohareb, Fahad |4 aut | |
| 700 | 1 | |a Alahmari, Ali |4 aut | |
| 700 | 1 | |a Aljurf, Mahmoud |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of hematology |d Springer Berlin Heidelberg, 1991 |g 101(2021), 2 vom: 31. Okt., Seite 421-428 |w (DE-627)130956759 |w (DE-600)1064950-5 |w (DE-576)025101188 |x 0939-5555 |7 nnns |
| 773 | 1 | 8 | |g volume:101 |g year:2021 |g number:2 |g day:31 |g month:10 |g pages:421-428 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00277-021-04708-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_4277 | ||
| 951 | |a AR | ||
| 952 | |d 101 |j 2021 |e 2 |b 31 |c 10 |h 421-428 | ||